每经AI快讯,有投资者在投资者互动平台提问:请问,国内领先的CRO企业药明康德、康龙化成是公司模式动物产品的客户吗?公司2023年在国内模式动物市的场占有率为多少?从2024年三季报看,公司的主营业务收入同比增长了12%,是否可以理解为公司2024年在国内的市占率同比是增长的?谢谢!药康生物(688046.SH)1月17日在投资者互动平台表示,药明康德、康龙化成均为公司客户。国内模式动物市场规模...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.